Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. The firm is citing strong Icotyde positioning right out of the gate as indicated in Johnson & Johnson (JNJ) Q1 earnings call, noting that comments around Ico potential see it as “one of their biggest products ever”, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
- Protagonist Therapeutics price target raised to $121 from $110 at Truist
- Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
- Protagonist price target raised to $110 from $107 at Leerink
- Protagonist Therapeutics price target raised to $120 from $112 at Citizens